Brainstorm Cell Therapeutics Inc. Class Action Lawsuit - BCLI
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Brainstorm Cell class action lawsuit seeks to represent purchasers or acquirers of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) publicly traded securities between August 15, 2022 and September 27, 2023, inclusive (the “Class Period”). Captioned Sporn v. Brainstorm Cell Therapeutics Inc., No. 23-cv-09630 (S.D.N.Y.), the Brainstorm Cell class action lawsuit charges Brainstorm Cell and certain of its top current executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Brainstorm Cell class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Brainstorm Cell class action lawsuit must be filed with the court no later than January 2, 2024.
CASE ALLEGATIONS: Brainstorm Cell is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer’s disease, and other neurodegenerative diseases.
The Brainstorm Cell class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Brainstorm Cell downplayed the severity of the U.S. Food and Drug Administration’s (“FDA”) refusal to file letter; and (ii) Brainstorm Cell continued to conceal the risks associated with the submission of its Biologics License Application.
The Brainstorm Cell class action lawsuit further alleges that on November 10, 2022, Brainstorm Cell issued a press release titled “BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS.” The Brainstorm Cell class action lawsuit alleges that following this announcement, the price of Brainstorm Cell stock fell more than 42%.
The Brainstorm Cell class action lawsuit further alleges that on September 27, 2023, Brainstorm Cell announced that members of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 17 to 1 that there was not substantial evidence to show NurOwn’s effectiveness. The Brainstorm Cell class action lawsuit alleges that on this news, the price of Brainstorm Cell stock fell more than 48%.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Brainstorm Cell publicly traded securities during the Class Period to seek appointment as lead plaintiff of the Brainstorm Cell class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Brainstorm Cell class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Brainstorm Cell class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Brainstorm Cell class action lawsuit.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller Rudman & Dowd LLP is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.